基本信息 产品详情 公司简介 推荐产品
网站主页 Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit
  • Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit-44689
  • Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit-44689
  • Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit-44689
  • Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit-44689

1/4

Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit-44689

Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit
¥9800 1Kit 起订
上海 更新日期:2026-11-17

上海优宁维生物科技股份有限公司

VIP6年
联系人:王
电话:15921930842拨打
手机:15921930842 拨打
邮箱:yh-wang@univ-bio.com

产品详情:

英文名称:
Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit
品牌:
CST
产品类别:
其他生物试剂
货号:
44689
一、产品概述

Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit 是来自CST品牌的高品质产品,适用于科研实验领域。

更多产品描述请查看优宁维官网(https://www.univ-bio.com/human-t-cell/44689T.html?mk_channel=chemicalbook)

二、产品信息
货号44689
SKU货号44689T
品牌CST
英文名称Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit
抗原名称Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC
研究领域癌症,免疫学和肿瘤学,
简单描述

Product Description

The Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit provides an economical means of detecting expression of receptors that modulate T cell activity in formalin-fixed, paraffin-embedded tissue samples.
三、背景
研究领域癌症,免疫学和肿瘤学,
背景

Background

PD-1 (PDCD1, CD279), TIM-3 (HAVCR2), LAG3 (CD223), VISTA (PD-H1), and B7-H3 (CD276) are immune cell co-inhibitory receptors (also known as immune checkpoints) that negatively regulate T cell function, and dampen the immune response to pathogens and cancer. In addition to activated T cells, PD-1 is expressed by activated B-cells and monocytes. TIM-3 is expressed by exhausted T cells in the settings of chronic infection and cancer. Tumor-infiltrating macrophages and dendritic cells also express TIM-3. LAG3 is primarily expressed by activated CD4+ T cells, CD8+ T cells, FoxP3+ T regulatory cells (Tregs) and natural killer (NK) cells. Although primarily expressed by myeloid cells, VISTA is also expressed by CD4+, CD8+, and Treg cells. Research examining the biological function of B7-H3 suggested that B7-H3 can be both a positive and negative regulator of T cell response. B7-H3 is expressed by antigen presenting cells, activated T cells, and a few normal tissues, including placenta and prostate. Expression of B7-H3 is seen in several cancer types, including prostate, breast, colon, lung, and gastric cancers, and in endothelial cells from tumor associated vasculature. Therapeutic blockade of these immune checkpoint receptors is a promising strategy for neoplastic intervention by enabling anti-tumor immune responses (1-3).

4-1BB (TNFRSF9, CD137), GITR (TNFRSF18), OX40 (TNFRSF4, CD134), and CD40 ligand (CD40L, CD154, TRAP, gp39) are immune cell co-stimulatory receptors that promote effector T cell survival and activation, and enable optimal immune responses to pathogens. 4-1BB is expressed in activated CD4+ and CD8+ T cells, natural killer cells and dendritic cells. GITR is expressed constitutively at high levels on Tregs, at low levels on naive and memory T cells, and is induced upon T cell activation. Studies show GITR can also be induced on NK cells, macrophages, and DCs. GITR ligation has been shown to induce CD8+ T cell activation, cytoxicity, and memory T cell survival, and conversely inhibit Treg suppressive function while promoting effector T cell resistance to Treg suppression. OX40 is primarily expressed on activated CD4+ and CD8+ T cells, while CD40L is primarily expressed on the surface of T cells, but has also been reported in blood platelets, mast cells, basophils, NK cells, and B cells. Research studies show that agonists of these co-stimulatory receptors augment anti-tumor immunity in several cancer types. Due to the combined effects on both Treg suppression and effector cell activation, GITR represents a unique opportunity for immunotherapeutic intervention in cancer. These pathways are an important area of interest in the study of cancer, vascular diseases, and inflammatory disorders (4-7).
  1. Schildberg, F.A. et al. (2016) Immunity 44, 955-72.
  2. Anderson, A.C. et al. (2016) Immunity 44, 989-1004.
  3. Callahan, M.K. et al. (2016) Immunity 44, 1069-78.
  4. Ward-Kavanagh, L.K. et al. (2016) Immunity 44, 1005-19.
  5. Ara, A. et al. (2018) Immunotargets Ther 7, 55-61.
  6. Knee, D.A. et al. (2016) Eur J Cancer 67, 1-10.
  7. Chester, C. et al. (2018) Blood 131, 49-57.

Alternate Names

autostainer; Bond; CD279; checkpoint blockade; checkpoints; co-inhibitory; co-stimulatory; immune checkpoint; immunotherapy; leica; PD-1; PD1; rx

四、产品特点
  • 品质保证:经过严格的质量控制,确保产品的高品质和稳定性。
五、注意事项
  • 本产品仅供科学研究使用,不可用于临床诊断或治疗。
  • 请在通风良好的环境下操作,佩戴适当的个人防护装备。
  • 如不慎接触皮肤或眼睛,请立即用大量清水冲洗并就医。
Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit

公司简介

上海优宁维生物科技股份有限公司(简称:优宁维,股票代码:301166)自2004年成立以来一直专注于抗体及相关产品,是国内专业、全面的抗体供应商和抗体专家,十多年来,正努力发展成为生命科学一站式供应商。公司总部位于上海,全国设有26个办事处,10个境内销售子公司。 我们长期聚焦于生命科学、生物医药、医疗诊断、分析检测等领域,公司整合了国内外50多家行业知名品牌,提供800多万种以抗体为核心的生命科学试剂、耗材、仪器、软件、定制、实验室服务、供应链服务等,形成了以第三方品牌产品为主、自主品牌产品为辅的全面供应体系,为更多的生命科学科研工作者提供专业、全面、安全、快捷的产品和服务。产品覆盖基因、蛋白、细胞、组织、动物等水平的各种研究。 公司2018年建立了南京研发中心,2021年筹建了杭州研发中心,并于2021年在南京投资建设GMP级生产中心,满足更多工业级客户的生命科学试剂需求。 公司秉承 向正 · 向善 · 向上 的价值观,以助力生命科学发展和创新为使命,在世界知名生物制品供应商为愿景下,砥砺前行。

成立日期 (23年)
注册资本 6500.000000万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 试剂,服务,试剂,服务
主营行业 生化试剂,生化试剂,抗体,抗体,蛋白组学,蛋白组学,分子生物学,分子生物学,免疫安全,免疫安全

Human T Cell Co-inhibitory and Co-stimulatory Receptor IHC Antibody Sampler Kit相关厂家报价

内容声明
拨打电话 立即询价